メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
藤田医科大学でコンテンツを検索
ホーム
プロファイル
研究部門
研究成果
医学部・血液内科学
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(4)
研究成果
(92)
フィンガープリント
医学部・血液内科学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Hematology
100%
Asciminib
100%
Leukemia Cell
83%
Subgroup Analysis
73%
T Cell
73%
Bleeding
72%
Febrile Neutropenia
66%
Imaging of Bone
66%
Chronic Myelogenous Leukemia
66%
Essential Thrombocythaemia
66%
Polycythemia vera
66%
Human Leukocyte Antigen
66%
T Lymphocyte Receptor
66%
Overall Survival
65%
Leukemia
64%
Tyrosine-Kinase Inhibitor
51%
Imaging Technique
50%
Drug Resistance
50%
Retrospective Study
50%
Bosutinib
45%
Two-Photon Microscopy
44%
Cytarabine
42%
Disease
42%
Nephropathy
41%
Central Nervous System
40%
Thrombosis
39%
Myelodysplastic Syndrome
38%
Factor Analysis
38%
Acute Myeloid Leukemia
38%
Myeloid Leukemia
37%
Retrospective Cohort Study
36%
COVID-19
33%
Prognostic Factor
33%
Mantle Cell Lymphoma
33%
Duodenum Ulcer
33%
Bone Marrow Microenvironment
33%
Hematopoietic Stem Cell
33%
Bloodstream Infection
33%
Fibroblast Growth Factor 2
33%
Acute Promyelocytic Leukemia
33%
Multiphoton Microscopy
33%
Ravulizumab
33%
Clinical Study
33%
Azacitidine
33%
Deferasirox
33%
Pure Red Cell Aplasia
33%
Cardiopulmonary Arrest
33%
Post-Hoc Analysis
33%
Antifungal Therapy
33%
Bone Tissue
33%
Micafungin
33%
NPM1
33%
Osteoblast
33%
Large-Cell Lymphoma
33%
Hepatitis B
33%
Hepatitis B Virus
33%
Leukemia Relapse
33%
Brentuximab Vedotin
33%
Pembrolizumab
33%
Waldenström's Macroglobulinemia
33%
Monoclonal Gammopathy of Undetermined Significance
33%
Circulating Tumor DNA
33%
Immunocompromised Patient
33%
Primary Central Nervous System Lymphoma
33%
Disease Burden
33%
Chromosome Aberration
33%
Nucleic Acid Amplification
33%
Myeloproliferative Neoplasm
33%
Symptomatic Treatment
33%
Core Binding Factor Beta
33%
Immunoglobulin A
33%
Cell Transplantation
33%
Vertebra
33%
Paraprotein
33%
Navitoclax
33%
Tumor Lysis Syndrome
33%
Hodgkin's Lymphoma
33%
Janus Kinase
33%
Neutrophil
33%
Cell Therapy
33%
Magnetic Resonance Imaging
33%
Hematopoietic Stem Cell
33%
Allotransplantation
33%
Cerebrospinal Fluid
33%
Incubation Time
33%
Adolescence
33%
Neoplasm
33%
Diffuse Large B-Cell Lymphoma
28%
Imatinib
28%
Allogeneic Hematopoietic Stem Cell Transplantation
27%
Acute Leukemia
26%
Platelet
26%
Cancer
25%
Symptom
25%
Bevacizumab
25%
Immune Deficiency
25%
Programmed Death-Ligand 1
22%
Classical Hodgkin Lymphoma
22%
Pre B Cell Receptor
22%
Disease Course
21%
Keyphrases
Predictive Significance
66%
Clinical Characteristics
66%
Hematology
66%
Asciminib
66%
Subgroup Analysis
41%
Thrombosis
37%
Retrospective Cohort Study
37%
D-index
37%
Leukemia Cells
37%
Rolling Adhesion
33%
Dynamic Analysis
33%
ILC2
33%
Differentiation Syndrome
33%
Third Harmonic Generation
33%
Nonlinear Optics
33%
Near-infrared Excitation
33%
Real-time Quantitative
33%
Second Harmonic Generation
33%
Febrile Neutropenia
33%
Multiphoton Excitation Microscopy
33%
Non-labeling
33%
Ravulizumab
33%
Cardiopulmonary Arrest
33%
Macrophage Targeting
33%
Dexamethasone Palmitate
33%
Gastroduodenitis
33%
Pure Red Cell Aplasia
33%
Deferasirox
33%
Mature Osteoblasts
33%
Chemoresistant
33%
Clasp
33%
Focal Adhesion Disassembly
33%
Promyelocytic Leukemia Zinc Finger
33%
VR-CAP
33%
Mantle Cell Lymphoma
33%
Cytarabine
33%
Antifungal Therapy
33%
Biomarker Monitoring
33%
Fungal Biomarkers
33%
Invasive Fungal Disease
33%
Micafungin
33%
Prognostic Implications
33%
NPM1 mutation
33%
Cell-mediated
33%
In Vivo Live Imaging
33%
Steno
33%
Hypoplastic Myelodysplastic Syndrome
33%
Randomized Controlled Non-inferiority Trial
33%
Diagnostic Biomarker
33%
3-hydroxykynurenine
33%
Kynurenic Acid
33%
Diffuse Large B-cell Lymphoma (DLBCL)
33%
Japanese Population
33%
Older Adults
33%
Flow Cytometric
33%
Chronic Myeloid Leukemia
33%
Refractory Hodgkin Lymphoma
33%
Circulating Tumor DNA (ctDNA)
33%
Spinal Cord
33%
Proton Density Fat Fraction
33%
Hematopoietic Function
33%
COVID-19 mRNA Vaccination
33%
Allogeneic Hematopoietic Stem Cell Transplant Recipients
33%
Renal Disease
33%
Neutrophil Count
33%
VPS13B
33%
Cohen Syndrome
33%
RUNX1-RUNX1T1
33%
KIT mutation
33%
CBFB-MYH11
33%
Japan
33%
Panel Sequencing
33%
Target Capture
33%
Molecular Landscape
33%
Monoclonal Gammopathy of Renal Significance
33%
Monoclonal Immunoglobulin
33%
Myeloproliferative Neoplasms
33%
Navitoclax
33%
Liposomal Contrast Agent
33%
Upper Part
33%
Dendron
33%
Magnetic Resonance Microimaging
33%
Polycythemia Vera
33%
Essential Thrombocythemia
33%
Nanoparticle Distribution
33%
Early Palliative Care
33%
Tools for Therapy
33%
Newly Diagnosed
33%
Cerebrospinal Fluid
33%
Nucleic Acid Amplification Test
33%
Lymphoplasmacytic Lymphoma
33%
COVID-19 Disease
33%
Japanese Subgroup Analysis
33%
Bosutinib
33%
ASCEM
33%
Baseline Analysis
33%
Lymphoma
33%
JAK2 mutation
26%
Imatinib
25%
Acute Myeloid Leukemia
22%
Pharmacology, Toxicology and Pharmaceutical Science
Asciminib
100%
Febrile Neutropenia
66%
Biological Marker
66%
Diffuse Large B Cell Lymphoma
66%
Thrombocythemia
66%
Chronic Myeloid Leukemia
66%
Chemotherapy
63%
Infection
54%
Protein Tyrosine Kinase Inhibitor
51%
Bosutinib
45%
Malignant Neoplasm
45%
Bleeding
41%
Kidney Disease
41%
Cohort Study
41%
Leukemia
40%
Disease
37%
Acute Myeloid Leukemia
33%
Mantle Cell Lymphoma
33%
Myelodysplastic Syndrome
33%
Colorectal Cancer
33%
Pharmacokinetics
33%
Two-Photon Microscopy
33%
Piperacillin Plus Tazobactam
33%
Bloodstream Infection
33%
Hospital Infection
33%
Promyelocytic Leukemia
33%
Syndrome
33%
Micafungin
33%
Antifungal Therapy
33%
Ravulizumab
33%
Paroxysmal Nocturnal Hemoglobinuria
33%
Seminoma
33%
Azacitidine
33%
Mycosis
33%
Community Acquired Infection
33%
Antiinflammatory Activity
33%
Zinc Finger and BTB Domain Containing Protein 16
33%
Retinoic Acid Receptor
33%
Promyelocytic Leukemia Protein
33%
Thrombomodulin
33%
Clinical Study
33%
3 Hydroxykynurenine
33%
Kynurenic Acid
33%
Retrospective Study
33%
Brentuximab Vedotin
33%
Pembrolizumab
33%
Hodgkin Disease
33%
Burkitt's Lymphoma
33%
Core Binding Factor Beta
33%
Circulating Tumor DNA
33%
Tumor Lysis Syndrome
33%
Navitoclax
33%
Paraprotein
33%
Monoclonal Immunoglobulinemia
33%
Polycythemia vera
33%
Benzodiazepine
33%
Immunocompromised Patient
33%
Piperacillin
26%
Imatinib
25%
Cytarabine
25%
Immune Deficiency
25%
Classical Hodgkin Lymphoma
22%
Pre B Cell Receptor
22%
Remission
19%
Kynurenine
18%
Drug Resistance
16%
Recombinant Thrombomodulin
16%
Haematoxylin
16%
Eosin
16%
Flavine Adenine Nucleotide
16%
Nicotinamide Adenine Dinucleotide
16%
Nicotinamide Adenine Dinucleotide Phosphate
16%
Splenomegaly
16%
Myelofibrosis
16%
First-Line Chemotherapy
14%
Anticoagulant Agent
13%
Galactomannan
13%
Glucan
13%
Recurrent Fever
13%
Bacterial Infection
13%
Minimal Residual Disease
13%
Liposome
13%
Myeloid metaplasia
13%
Hematologic Malignancy
12%
Antiinfective Agent
12%
Refractory Anemia with Excess Blasts
11%
Dexamethasone Sodium Phosphate
11%
Mouse
11%
Hypnotic
11%
Ribosome Protein
11%
Clinical Trial
10%
Adverse Event
9%
Overall Survival
9%
Complement Inhibitor
9%
Neoplasm
8%
Minodronic Acid
8%
Proton Pump
8%
Mouse Model
8%
COVID-19 Vaccine
8%
Rheumatic Disease
8%